Company intelligence / Profile preview
RetroVirox
San Diego, California, United Statesretrovirox.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
RetroVirox develops novel small-molecule immunomodulators targeting HIV eradication and cancer therapy. It also provides extensive antiviral assay services to biotech/pharma clients worldwide. Its pipeline includes preclinical candidates for HIV cure strategies using new mechanisms of action that block viral entry. The company has received over $5 million in NIH SBIR grants to support its research efforts.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculeImmunomodulatorBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Not specifically listed by name; collaborates with hundreds of biotech/pharma companies globally through fee-for-service or FTE contracts for antiviral testing.
Beyond the preview
Go deeper on RetroVirox.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RetroVirox.